Product Highlight - Abstral

01 May 2018
Product Highlight - Abstral
ABSTRAL - Fentanyl citrate 100 mcg, 200 mcg and 400 mcg SL tab - A. Menarini


• The first sublingual formulation of fentanyl citrate approved for the treatment of Breakthrough Cancer Pain
Rapid onset
• Quick dissolution allows for rapid transmucosal absorption of fentanyl
Treatment optimisation
• Can be titrated within the recommended dosing regimen to meet the
analgesic requirements of individual patients
Designed for convenient administration
• Non-invasive
• Easy to use

Reference: Abstral Package insert_230217

Further information is available in section 4j, New In This Issue and
Full prescribing information is available upon request.

Related MIMS Drugs

Editor's Recommendations